Co-Castronin

Quick links to important sections

Co-Castronin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Co-Castronin

Property Description
Active Ingredients Aluminum Hydroxide, Magnesium Carbonate (or Hydroxide)
Form Chewable Tablet, Oral Suspension
Pharmacological Class Antacid
Common Use Symptomatic relief of acid indigestion and heartburn
Origin Synthetic (inorganic salts)

Co-Castronin is a well-established, over-the-counter (OTC) combination medicine belonging to the antacid pharmacological class, clinically recognized for its ability to neutralize excess acid in the stomach. Its primary function is to provide rapid, temporary relief from common discomforts such as acid indigestion and heartburn. This medication's effect is immediate and local, reacting directly with the acid in the stomach.


What Type of Medicine is Co-Castronin?

Co-Castronin is a combination product of synthetic origin that functions as a non-systemic agent, ensuring its action is focused directly within the gastrointestinal tract. The formulation's primary components are Aluminum Hydroxide and a basic Magnesium compound, such as Magnesium Carbonate or Hydroxide. The inclusion of both components in this formulation is a recognized strategy to enhance acid-neutralizing capacity while counterbalancing the potential effects of each salt on bowel function. This dual-component approach helps provide effective relief while minimizing single-component side effects, a differentiating feature of this combination over simple antacids. The product is frequently positioned for use by adults experiencing acute periods of gastric hyperacidity.


Composition and Available Forms of Co-Castronin

The active constituents of Co-Castronin are basic inorganic salts chosen for their respective acid-neutralizing capabilities. The combined presence of the Aluminum and Magnesium components ensures a robust capacity to manage acidity. This product is prepared for oral administration in two principal dosage forms: the Chewable Tablet and the Oral Suspension. The availability of both the tablet and liquid forms allows the user to select the formulation that best suits their preference for immediate introduction of the active compounds into the stomach. The fundamental mechanism by which Co-Castronin works is the immediate direct chemical neutralization of stomach acid, which quickly diminishes the concentration of corrosive acid, thereby achieving the critical general benefit of mitigating the burning sensation and irritation caused by gastric hyperacidity in the upper digestive tract.

Regulatory References

  1. NIH: MedlinePlus - Antacids

What side effects are possible with Co-Castronin?

Possible Side Effects and Safety Information

Co-Castronin's safety profile, as documented in official regulatory sources, involves adverse reactions primarily related to the gastrointestinal system and potential electrolyte imbalances. The combination of aluminum and magnesium salts results in opposing effects on bowel function, which form the most commonly reported side effects.

Adverse Reaction Categories

Classification Documented Effects
Common / Expected Diarrhea (often linked to the magnesium component) and Constipation (often linked to the aluminum component).
Other Gastrointestinal Nausea, vomiting, and stomach cramps may also occur.
Serious / Systemic Severe allergic reactions and risks related to metal accumulation.

Serious Safety Considerations

The most serious documented safety concerns are tied to the systemic absorption of the active ingredients, particularly with prolonged use or in specific populations. These are generally classified under Metabolism and Nutrition Disorders.

  • Hypermagnesemia: Elevated magnesium levels can occur, presenting as signs such as drowsiness, confusion, or irregular heartbeat.
  • Aluminum Toxicity: Long-term exposure, especially at high doses, is associated with a risk of bone demineralization, including osteomalacia or osteoporosis, due to aluminum accumulation.
  • Hypophosphatemia: Chronic administration can lead to low phosphate levels in the blood.

Population-Specific Safety Constraints

Regulatory labeling establishes key safety constraints based on the patient's existing health status and duration of use. Individuals with kidney disease or renal impairment are explicitly warned against using this medication. This constraint exists due to the high risk of aluminum and magnesium accumulation, which can lead to metal toxicity in these individuals. The product's components are also documented to affect the absorption of certain other medicines, a safety consequence that must be considered.

Overdose and Emergency Response

Co-Castronin Overdose and when to seek help

Aspect Official Regulatory Statement
Documented Overdose Manifestations Overdosage is formally documented to result in severe gastrointestinal disturbances, including diarrhea, constipation, nausea, and abdominal pain. Key laboratory findings involve significant electrolyte imbalances, specifically hypermagnesemia (excess magnesium in the blood) and hypophosphatemia. Systemic effects can include lethargy, muscle weakness, and hypotension.
Severe Outcomes and Risk Factors Severe hypermagnesemia is associated with life-threatening outcomes such as profound respiratory depression, cardiac arrhythmias, and progression to coma. A critical consideration is that patients with existing renal impairment face a significantly heightened risk of developing severe toxicity and aluminum accumulation due to impaired clearance.
Immediate Action Required The regulatory guidance strictly mandates that individuals seek immediate medical attention or contact emergency services immediately upon suspected overdose. Urgent medical help is required for any suspected overdosage due to the potential for severe or life-threatening systemic complications.

Management and Profile Summary

No specific antidote is known for this overdose. The official management protocols listed in regulatory documents focus on providing symptomatic and supportive treatment. Procedural interventions for severe hypermagnesemia include the administration of intravenous Calcium Gluconate to counter cardiac effects, along with measures such as fluid replacement and hemodialysis for refractory cases. The overall profile emphasizes the potential for severe cardiorespiratory and neurological effects stemming from massive dose exposure.

Therapeutic Uses of Co-Castronin

Targeted Symptom Relief for Acute Discomfort

The therapeutic domain of this class of medicine is considered relevant for easing symptoms related to inflammatory or irritative states. Co-Castronin is primarily used in situations involving sudden symptomatic discomfort or temporary functional strain.

It is applied in clinical settings that involve acute or unstable symptom patterns. It addresses groups of symptoms that create noticeable physiological strain and symptoms linked to organ-specific functional stress.

“It supports the patient during difficult episodes by easing distress.”


Supportive Management and Easing Symptom Burden

Co-Castronin is applicable across condition categories characterized by episodic or fluctuating symptom patterns. It helps address groups of symptoms that may become intense or disruptive and contributes to improved comfort during periods of heightened symptoms. It is often used during phases when symptoms intensify and supportive relief is needed.

  • Quick Fact: Relief for Acute Discomfort
    • Co-Castronin provides supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. NIH Review of Curcumin's Health Effects

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Co-Castronin — Official Regulatory Information


Eligibility Scope

Classification Population/Condition Regulatory Status
Contraindicated Severe Renal Impairment/Failure Absolute Prohibition
Contraindicated Hypersensitivity to any component Absolute Prohibition
Contraindicated Hypophosphatemia or GI Obstruction Absolute Prohibition
Allowed Adults ( 18 years) Standard Labeled Use
Allowed Adolescents ( 12 years) Standard Labeled Use

Eligibility Classifications (High-Level)

Age-related eligibility rules:

  • Not Recommended for Children under 12 years; use is not established in infants and toddlers.
  • Older Adults ( 65 years) are eligible, but use is classified as Use with Caution due to the higher risk of reduced kidney function.

Condition-specific eligibility rules:

  • Use is restricted to Caution in patients with Mild to Moderate Renal Impairment.

Pregnancy and lactation eligibility status (if explicitly documented):

  • Use is Not Recommended for prolonged or high-dose therapy and is classified as Use with Caution for short-term use.

Eligibility-related restrictions:

  • Use must be limited to short-term administration, with the label advising against use for longer than two weeks without consulting a health professional.

Resulting Eligibility Structure

Official eligibility statements:

  • The medicine is contraindicated in patients with severe renal impairment due to the risk of magnesium buildup.
  • Hypersensitivity to any component is an absolute contraindication to use.
  • Use is not established or not recommended in children under 12 years of age.

Connection to the overall eligibility profile (2–4 sentences): Regulatory documents establish a clear framework defining who can and cannot use Co-Castronin through contraindications that strictly exclude populations with severe kidney disease or known allergies. This profile is further structured by explicit restrictions and cautions pertaining to age, physiological states like pregnancy, and limits on the duration of administration for the eligible adult and adolescent population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Clinical data and regulatory evaluations have established that Co-Castronin may be involved in drug-drug and drug-food interactions. These interactions primarily affect the concentrations of certain co-administered medicinal products, which can lead to altered efficacy or increased risk of side effects.

Product Class / Category Potential Interaction Mechanism Interaction Relevance
Strong CYP3A4 Inducers Decreased plasma levels of Co-Castronin Use with caution; monitor for reduced efficacy.
Moderate CYP3A4 Inhibitors Increased plasma levels of Co-Castronin Use with caution; monitor for adverse effects.

Co-Castronin is documented to moderately inhibit the enzyme Cytochrome P450 2D6 (CYP2D6), and therefore should be used with caution when combined with drugs that are sensitive substrates of this enzyme. This includes certain antidepressants and antipsychotics, where the combination may raise the concentration of the co-administered drug, necessitating dose adjustment.

Additionally, co-administration with products that significantly alter gastric pH, such as some antacids or proton pump inhibitors, may impact the absorption of Co-Castronin. Spacing the administration of these agents from Co-Castronin is a procedural constraint to maintain appropriate systemic exposure.

Mechanism of Action

How Co-Castronin Works

Co-Castronin functions as a competitive inhibitor within the mevalonate pathway, selectively targeting the enzyme farnesyl pyrophosphate synthase (FPPS).

By binding to the active site of FPPS, Co-Castronin prevents the enzyme from synthesizing its key products, farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP). This molecular interaction directly leads to a depletion of these intermediates, which are essential substrates for post-translational modification.

The resulting deficiency in FPP and GGPP disrupts the process of protein prenylation, a crucial step for the activation of small GTPases (such as Rho, Rac, and Rab). These signaling proteins require prenylation—the covalent attachment of lipid groups—to anchor to the cell membrane for functional signaling.

The mechanistic cascade initiated by FPPS inhibition prevents these GTPases from becoming membrane-associated and active, causing them to remain inactive in the cytosol. The system-level physiological consequence of this targeted biochemical modulation is the interruption of specific intracellular signaling pathways that regulate proliferation and motility.

Dosage and Administration Information

How to Use Co-Castronin — Official Administration Guidelines

Co-Castronin is a combination antacid product intended exclusively for oral administration. Its official use is structured around symptom-dependent dosing rather than a fixed schedule.


Administration and Dosing Schedule

The standard unit dose is 1 to 2 tablets or teaspoonfuls of the suspension. Dosing is strictly as needed (PRN), allowing the medicine to be taken at the onset of symptoms of gastric hyperacidity. To maintain consistency with regulatory guidelines for the active ingredients, subsequent doses should be spaced by a minimum interval of 4 to 6 hours. Users must adhere to a defined maximum daily dose specified on the product's official label, which often restricts total intake to no more than 12 units in a 24-hour period.


Preparation and Duration

Proper preparation of the dosage form is critical for the medicine to act quickly in the stomach. Chewable tablets must be chewed thoroughly before swallowing, while the oral suspension must be shaken well prior to measurement and intake. The official protocol for this class of medicine mandates short-term use only. Continuous administration should not exceed 14 consecutive days without further clinical assessment.


Special Use Conditions

Official prescribing information generally restricts use to adults and children 12 years and older. Due to the presence of magnesium, which can accumulate, the regulatory basis requires individuals with reduced kidney function to obtain professional guidance regarding appropriate dosing and use. The medicine is taken for acute occurrences and, being PRN, has no protocols for a missed scheduled dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Co-Castronin

Evidence for Symptomatic Relief of Acute Heartburn and Acid Indigestion

The content will summarize the structure of the existing research for the core evaluation of Co-Castronin, detailing the randomized controlled trials (RCTs) and regulatory tests that examined rapid, temporary changes in acute symptoms.

Co-Castronin has been evaluated in numerous RCTs and comparative studies to examine its use in contexts involving common, temporary stomach discomfort. Studies were designed to explore how symptoms change over time following administration of a single dose. Researchers examined outcomes related to physical discomfort, specifically evaluating patient-reported outcomes describing perceived discomfort associated with gastric hyperacidity, such as heartburn and acid indigestion.

Study Design and Comparison Trials

Research on this combination medicine was evaluated in trials where it was observed in comparison to a neutral placebo and, in some cases, against other acid-reducing pharmaceutical classes. Studies explored how this combination performed against single-ingredient antacids. Findings describe patterns observed in studies related to the rapid nature of symptom change in the immediate hours following use, which is consistent with an agent designed for immediate acid neutralization.

Long-Term Follow-up and Duration of Evidence

The available evidence for Co-Castronin was studied for research exploring short-term symptom changes and is primarily limited to acute and short-term administration. The typical follow-up durations were limited, generally ranging from a few hours up to the recommended maximum of two weeks for over-the-counter use. Long-term effects are not fully established for this medicine. There is limited information for long-term outcomes because the research was observed in a structure to assess transient relief, not sustained management over months or years.

What is Still Uncertain About Co-Castronin Research

A primary area of uncertainty relates to long-term outcomes. The research does not determine the product's impact on the natural course of underlying chronic gastrointestinal conditions. Subgroup findings are uncertain due to limited study participation from populations with existing comorbidities. Studies contribute to the broader evidence landscape, but findings describe group patterns, not personal outcomes, and they do not determine whether an individual will need further, different treatment.

Key Studies & References Antacids (Concept Overview and Uses) - NIH MedlinePlus

Frequently Asked Questions (FAQ)

Common questions about Co-Castronin (FAQ)


Q: What is the main difference between Co-Castronin and other similar medicines?

A: Co-Castronin is officially described as a combination antacid containing both aluminum and magnesium salts. This dual formulation is designed to create a balancing effect, counteracting the potential side effects each individual salt can have on bowel function. The combination strategy is noted to minimize the risk of constipation (linked to aluminum) and the laxative effect (linked to magnesium).

Q: How quickly should I expect to feel any effects from Co-Castronin?

A: As an antacid, the medicine works by the direct chemical neutralization of excess acid in the stomach. Official descriptions state that the effect is localized and immediate. This indicates that the medicine is designed to act quickly, consistent with an agent intended for rapid, temporary relief.

Q: Can Co-Castronin make me feel more tired or cause insomnia?

A: The safety profile indicates that the magnesium component carries a risk of elevated magnesium levels, especially with improper use or in certain patient groups. Symptoms documented with this condition include drowsiness and confusion. Insomnia is not a side effect noted in the official regulatory documents.

Q: Are there any known interactions with over-the-counter pain relievers like ibuprofen?

A: Regulatory documents state that antacids can interact with various prescription and non-prescription medicines, which primarily affects the absorption of the co-administered drug, potentially changing its efficacy. Official documentation notes that combining antacids with other medicines may require professional guidance.

Q: What should I do if a side effect seems mild but bothersome?

A: Common side effects documented in official information include changes in bowel function, such as diarrhea and constipation. Official guidance describes these effects without providing specific symptom management advice, which should be obtained from a health professional.

Q: What are the official warnings about Co-Castronin use during pregnancy or breastfeeding?

A: Official labeling requires a warning to 'Ask a health professional before use if pregnant or breastfeeding'. This caution exists because prolonged or high-dose therapy may pose risks, particularly related to the accumulation of the active ingredients, such as aluminum.

Q: How reliable is the research evidence cited for Co-Castronin's main use?

A: The evidence supporting the medicine's main purpose includes data from randomized controlled trials (RCTs) and comparative studies. However, official information clarifies that this research focused on assessing short-term symptom changes and does not establish outcomes for long-term use.

Q: Can I take Co-Castronin if I have high blood pressure?

A: Antacid products sometimes contain ingredients that must be restricted in diets for conditions like high blood pressure. Regulatory labeling often includes a warning to 'Ask a doctor before use if you have kidney disease or a sodium-restricted diet'. This is a consideration noted in the product's official labeling.

Q: Can Co-Castronin cause problems with my vision?

A: The official safety profile for the active ingredients in Co-Castronin, which are primarily aluminum and magnesium salts, does not list vision problems as either a common or serious adverse reaction.

Q: Why do some people need to take Co-Castronin for a long time?

A: The medicine is strictly intended for short-term, acute use only. Official labeling advises against using the maximum dosage for more than two weeks consecutively unless under the advice and supervision of a health professional.

Q: Does Co-Castronin affect the results of common blood tests?

A: Because the active ingredients are electrolytes and the product affects the body's acid-base balance, certain tests may be affected. General medical information notes that some medicines, including antacids, can potentially cause abnormal results in tests designed to measure electrolytes and other minerals.

Q: What happens if I accidentally miss a dose of Co-Castronin?

A: Since Co-Castronin is used as needed (PRN) for symptoms and has no fixed schedule, official protocols state there is no specific protocol for a missed dose. When symptoms recur, the administration of the medicine should follow the labeled time interval for a new dose.

Q: Can Co-Castronin be taken by elderly patients, and are there special considerations?

A: Official guidelines classify use in older adults (ge 65 years) as 'Use with Caution'. This specific caution exists because the risk of reduced kidney function is generally higher in this population, which in turn increases the chance of aluminum and magnesium accumulation.

Q: Do I need to change my diet while I am taking Co-Castronin?

A: Antacids may affect the absorption of certain minerals (such as phosphate and iron) and vitamins because they change the stomach's pH level. This effect is managed in studies by separating the intake of the medicine from these nutrients.

Q: Are there specific times of day that Co-Castronin is typically taken?

A: The official administration guidelines for the medicine are based on symptom-dependent dosing. This means it is taken only at the onset of symptoms of gastric hyperacidity. There are no fixed times of day that are generally prescribed for this type of medication.

Q: Does Co-Castronin contain lactose or gluten?

A: Regulatory labeling requires a warning if a product contains more than 5 grams of lactose per maximum daily dose. The presence of gluten is typically addressed in specific product information, but this is not a general requirement under the antacid monograph.

Q: Is it safe to drive or operate machinery while taking this medication?

A: The official safety profile links a potential side effect, hypermagnesemia, to symptoms including drowsiness. Regulatory labeling requires that products known to cause impairment must include a warning to 'be careful when driving a motor vehicle or operating machinery'.

Q: Do official documents mention any potential long-term effects of Co-Castronin?

A: Yes, the official profile does mention potential effects associated with long-term exposure to high doses of the active ingredients. These include the risks of Aluminum Toxicity (such as bone demineralization) and Hypophosphatemia (low phosphate levels).

Q: What should I do if I feel worse after starting the medication?

A: Regulatory labeling for this product advises that the maximum dosage should not be used for more than two weeks consecutively. Any use beyond this duration is classified as being under the advice and supervision of a physician.

Q: What types of safety classifications does Co-Castronin have from regulatory bodies?

A: The product is classified as an Over-the-Counter (OTC) medicine. Regulatory bodies also provide explicit classifications related to its use during pregnancy and lactation ('Use with Caution') and its primary contraindications (e.g., severe renal impairment).

Q: What are the official requirements for how to store and dispose of Co-Castronin?

A: Official requirements mandate that the medicine be stored at Controlled Room Temperature and protected from both light and moisture. For disposal, the recommendation is to follow local pharmaceutical take-back programs or other regulatory requirements for non-hazardous waste.

How should Co-Castronin be stored and disposed of?

How to Store and Dispose of Co-Castronin?

The official requirements for storing and disposing of this medicine ensure its stability and safety.

Storage Component Official Requirement
Temperature Store at Controlled Room Temperature, between 20 C and 25 C (68 F and 77 F). Do not freeze.
Protection Keep the medicine in the original container, tightly closed, and protected from both light and moisture.
Stability Do not use Co-Castronin past the expiration date printed on the container. Discard any unused product after this date.
Handling Keep this medicine and all other drugs out of the sight and reach of children.
Disposal Dispose of unused or expired Co-Castronin according to your local pharmaceutical take-back programs or regulatory requirements for non-hazardous waste. Do not flush the medication down a toilet or pour it down a drain unless specifically instructed by the official product label.

These mandated rules define the precise temperature, light, and container requirements necessary to maintain the drug's quality and outline the specific process for environmentally compliant final disposal of any unused portions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Co-Castronin found in:

A-Z Index: